I bought an opioid at the gas station, and it was legal. That’s a problem.

The juxtaposition in this story is jarring: a physician’s prescription pad is scrutinized, logged, and limited, yet a gas station shelf can offer a substance with comparable or greater potency without a single question. On one side, advocates for stricter regulation see this as a glaring failure of the system—a loophole that allows dangerous opioids to bypass the very safeguards designed to prevent addiction and overdose. They argue that if we treat prescription opioids with caution, we must apply the same logic to synthetic analogs sold as “legal highs” or unapproved supplements. On the other side, some libertarian-minded readers might point to the dangers of over-regulation, warning that banning substances often drives them underground, creating even more hazardous black markets. They might also question the accuracy of the “13 times stronger” claim, noting that potency comparisons can be misleading without context on dosage and formulation. Yet even they would likely agree that the current situation—where a gas station can sell a potent opioid with no labeling, no dosing guidance, and no age verification—is a recipe for harm. What makes this story compelling is its framing of inconsistency as a public health hazard. The author isn’t calling for a blanket ban on all opioids; rather, they’re highlighting how our patchwork of laws creates arbitrary distinctions. A patient in pain faces bureaucratic hurdles, while a curious teenager can buy a dangerous substance next to a breakfast taquito. This isn’t a partisan issue—it’s a governance issue, and it forces us to ask whether our regulatory framework is truly protecting the public or merely shifting risk to unregulated corners. The broader theme here is the challenge of keeping pace with synthetic chemistry. As novel opioids are developed faster than laws can be updated, the gap between prescription and over-the-counter widens. Whether the solution lies in stricter enforcement, reclassification, or public education, the conversation must begin with acknowledging that the current system is out of sync. The source article (https://thehill.com/opinion/healthcare/6082262-candy-flavored-opioid-controversy/) serves as a timely reminder that the opioid crisis is not just a prescription problem—it’s a problem of access, oversight, and consistency in how we treat dangerous substances. </summary> <!-- Oops, I mistakenly put a summary tag here. Actually the commentary should be inside <commentary> tags. Let me correct that. --> Wait, I made a mistake. The response should have three separate tags: <summary>, <commentary>, <ai_thoughts>. I accidentally put a closing </summary> inside the commentary. Let me fix that. I'll rewrite the whole response properly. <summary> A recent opinion piece in The Hill highlights a stark regulatory inconsistency: while surgeons face strict oversight when prescribing even a few days of opioid pain relief, a consumer can legally purchase a synthetic opioid (allegedly 13 times stronger than morphine) at a gas station. The author, a surgeon, argues this legal loophole undermines public health efforts and sends a confusing message about drug safety. The piece calls for urgent regulatory action to close the gap between prescription opioids and unregulated over-the-counter substances, while acknowledging the complexity of balancing access and control. </summary> <commentary> The juxtaposition in this story is jarring: a physician’s prescription pad is scrutinized, logged, and limited, yet a gas station shelf can offer a substance with comparable or greater potency without a single question. On one side, advocates for stricter regulation see this as a glaring failure of the system—a loophole that allows dangerous opioids to bypass the very safeguards designed to prevent addiction and overdose. They argue that if we treat prescription opioids with caution, we must apply the same logic to synthetic analogs sold as “legal highs” or unapproved supplements. On the other side, some libertarian-minded readers might point to the dangers of over-regulation, warning that banning substances often drives them underground, creating even more hazardous black markets. They might also question the accuracy of the “13 times stronger” claim, noting that potency comparisons can be misleading without context on dosage and formulation. Yet even they would likely agree that the current situation—where a gas station can sell a potent opioid with no labeling, no dosing guidance, and no age verification—is a recipe for harm. What makes this story compelling is its framing of inconsistency as a public health hazard. The author isn’t calling for a blanket ban on all opioids; rather, they’re highlighting how our patchwork of laws creates arbitrary distinctions. A patient in pain faces bureaucratic hurdles, while a curious teenager can buy a dangerous substance next to a breakfast taquito. This isn’t a partisan issue—it’s a governance issue, and it forces us to ask whe